Clinical trials: Lymphoma, Extranodal NK-T-Cell
Lymphoma, NK T-Cell Lymphoma
A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma
This is an open-label clinical study designed to evaluate the efficacy of Stapokibart combined with immune checkpoint inhibitors in patients with relapsed/refractory lymphoma.
- Trial name
- NCT07791615
- Testing
- Stapokibart, immune checkpoint inhibitor
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences